Latest News HighLights
Bevacizumab biosimilar by Gedeon Richter for Metastatic Breast Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase I drugs for Metastatic Breast Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Smarter leaders trust GlobalData The gold standard of business intelligence. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Bevacizumab biosimilar overview Bevacizumab biosimilar is under development for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic breast cancer, glioblastoma and metastatic renal cell carcinoma. The drug candidate is administered through intravenous route. It is a recombinant humanized monoclonal antibody that targets the human vascular endothelial growth factor A (VEGF-A). It is developed using selexis sure technology. The technology is based on DNA elements that control the dynamic organization of chromatin within cells and allow for higher and stable expression of recombinant proteins. Gedeon Richter overview is a pharmaceutical company that develops, manufactures and markets a wide range of drugs including original, generic, and licensed products and over the counter (OTC) medicines. The company’s product portfolio consists of medicines to treat gynecological diseases, gastrointestinal diseases, cardiovascular diseases and central nervous system disorders. Richter’s research activities focus exclusively on the development of original small molecules, recombinant biotechnology, and generic product development. It operates sales network in Hungary, Central Eastern Europe, and the Commonwealth of Independent States (CIS) countries. The company has a research and development unit in Central Eastern Europe. is headquartered in Budapest, Hungary. For a complete picture of Bevacizumab biosimilar’s drug-specific PTSR and LoA scores, This content was updated on 9 October 2023 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s . Smarter leaders trust GlobalData The gold standard of business intelligence.
Publish Date : 2023-10-27 21:51:20
Image and News Source : pharmaceutical_technology
